Arachidonic acid metabolism: A primer for head and neck surgeons

Head and Neck

Volumn 20, Issue 4, 1998, Pages 334-349

  Ondrey, Frank G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cyclooxygenase; Eicosanoids; Head and neck cancer; Immunity; Lipoxygenase; Prostaglandins

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; LEUKOTRIENE; LIPOXYGENASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE C; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; THROMBOXANE SYNTHASE;

ARACHIDONIC ACID METABOLISM; ENZYME SYNTHESIS; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; ICOSANOID METABOLISM; LIPID METABOLISM; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0031897158     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0347(199807)20:4<334::aid-hed9>3.0.co;2-%23     Document Type: Review

References (93)

1. Smith EL, Hill RL, Lehman IR, Lefkowitz RJ, Handler P, Abraham White, eds. Principles of biochemistry, chapter 13. New York: McGraw-Hill Book Company, 1983.
2. Abrahamsson S, Bergstrom S, Sameulsson B. The absolute configuration of PG F2-1. J Chem Soc 1962;332.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971; 231:232-235.
4. Samuellson B, Borgeat P, Hammarstrom S, Murphy R. Leukotrienes: a new group of biologically active compounds. Adv Prost Thromb Res 1980;6:1-19.
5. Kutchera W, Jones D, Matsunamai N, et al. PG H Synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci 1996;93:4816-4820.
6. Vance D, Vance JE, eds. Biochemistry of lipids, lipoproteins and membranes. Amsterdam: Elsevier, 1991.
7. Gerrard JM. Neutrophils. In Gerrard J, (ed.) Prostaglandins and leukotrienes: blood and vascular function. New York: Marcel Dekker, Inc, 1985:117-135.
8. Pryor W, ed., Free radicals in biology. New York: Academic Press, 1982.
9. Cunningham FM, ed. Lipid mediators. London: Academic Press, 1994.
10. Alberts B, ed. The plasma membrane. Molecular biology of the cell. New York: Garland Publishing, 1983.
11. Lands, WE. Fish and human health. Orlando: Academic Press, 1986.
12. Clark J, Schievella A, Nalefsk E, et al. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal 1995;12:83-117.
13. Gelb M, Jain M, Berg. Inhibition of phospholipase A2. FASEB J 1994;8:915-924.
14. Roberts M. Phospholipases: structural and functional motifs for working at an interface. FASEB J 1996;10: 1159-1172.
15. Vance D, Vance JE, eds. Biochemistry of lipids, lipoproteins and membranes. Amsterdam: Elsevier, 1991.
16. Herschman H. Regulation of prostaglandin production in activated mast cells. Eicosanoids & other bioactive lipids in cancer. Inflammation Rel Dis 1997;3.
17. Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipases in generating lipid second messengers in signal transduction. FASEB J 1991;5:2068-2077.
18. Divecha N, Irvine RF. Phospholipid Signal Cell 1995;80: 269-278.
19. Balsinade J, Diez E, Mollinedo F. Arachidonic acid release from diacyl glycerol in human neutrophils. J Biol Chem 1991;266:15368-15373.
20. von Euler US. A depressor substance in the vesicular gland. J Physiol 1935;84:21p-22p.
21. Johnson M, Carey F, McMillan R. Alternative pathways of arachidonate metabolism: prostaglandins, thromboxanes, and leukotrienes. Essays in biochemistry 1983;19:40-141.
22. Lands WE. Biosynthesis of prostaglandins. Ann Rev Nut 1991;11:41-60.
23. Funk C. Molecular biology of the eicosanoid field. Prog Nuc Acid Res Mol Biol 1993;45:67-98.
24. Smith W, Garavito R, and DeWitt D. Prostaglandin endoperoxide H synthases-1 and -2. J Biol Chem 1996;271: 33157-33160.
25. Hemler M, Land WE. Evidence for a peroxide-initiated free radical mechanism of prostaglandin biosynthesis. J Biol Chem 1980;255:6253-6256.
26. Munroe D, Ang E, MacIntyre P, et al. Novel intracellular signaling function of PG H synthase-1 in NF-kappa B activation. J Inflammation 1995;45:260-268.
27. Robbins SL, ed. Pathologic basis of disease, The Gastro-intestinal Tract, Philadelphia: W.B. Saunders Company, 1984:867-868.
28. Giardello F, et al. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
29. Liu X, Rose D. Differential expression and regulation of cyclooxygenase-1 and -2 in two breast cancer cell lines. Cancer Res 1996;56:5125-5127.
30. Tang DG, Honn KV. Eicosanoids and tumor cell metastasis. In: Harris JE, Braun DP, Anderson KM, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.
31. Pinto S, Gori L, Gallo O, et al. Increased thromboxane A2 production at the primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostagland Leukotr Essent Fatty Acids 1993;49:527-530.
32. Gullino P. Prostaglandins and gangliosides of the tumor microenvironment: their role in angiogenesis. 1995;34: 439-441.
33. Reich R, Martin G. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996;51:1-17.
34. Lala PK, Saarloos MN. Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: Harris JE, Braun DP, Anderson KM, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.
35. Rappoport SM, Schewe T, Wiesner R, et al. The lipoxygenase of reticulocytes. Eur J Biochem 1979;96:545-561.
36. Rokach J, Fitzsimmons B. The lipoxins. Int J Biochem 1988;20:753-758.
37. Radmark O. Arachidonate 5-lipoxygenase. J Lipid Mediat Cell Signal 1995;12:171-184.
38. Vickers P. 5-Lipoxygenase activating protein. J Lipid Mediat Cell Signal 1995;12:185-194.
39. Ford-Hutchinson AW. Regulation of leukotriene biosynthesis. Cancer Metastases Rev 1994;13:257-267.
40. Semplicini A, Valle R. Fish oils and their possible role in the treatment of cardiovascular disease. Pharmacol Therapeut 1994;61:385-397.
41. Lee T, Austen KF. Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Adv Immunol 1986;39:145-175.
42. Singh J, Hamid R, Reddy B. Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 1997;57:3465-3470.
43. Noguchi M, Minami M, Kinoshita K, et al. Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br J Cancer 1997;75:348-353.
44. Das U. Gamma-linolenic acid, arachidonic acid, and eicosapentaneoic acid as potential anti-cancer drugs. Nutrition 1990;6:429-434.
45. Shin D, Tainsky MA. Molecular phenotyping of head and neck cancer. Cancer Treat Res 1995;74:1-42.
46. Maisel RH, Ogura JH. Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count: predictors of survival in head and neck cancer. Ann Otolaryngol 1976;85: 517-522.
47. DeVita V, Hellman S, and Rosenberg S, eds. Biologic therapy of cancer. Philadelphia: J.B. Lippincott and Co, 1991.
48. Cross D, Ondrey F, Juhn S, Adams G. Prostaglandins and host immune response in squamous cell carcinoma of the head and neck. In: Harris JE, Braun DP, Anderson KM, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.
49. Katz A. Immunobiologic staging of patients with carcinoma of the head and neck. Laryngoscope 1983;93: 445-463.
50. Harris J, Sengar D, Stewart T, et al. The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 1976;37:1058.
51. Oettgen H, Livingston P, Old L. Immunotherapy by active specific immunization: clinical applications - melanoma. In: DeVita V, Hellman S, Rosenberg, eds. Biologic therapy of cancer, Philadelphia: J.B. Lippincott and Co., 1991.
52. Liu X, Connolly J, Rose D. Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line. Clin Exper Metastases 1996;14:145-152.
53. Buckman D, Hubbard NE, Erickson K. Eicosanoids and linoleic acid-enhanced growth of mouse mammary tumor cells. Prost Leak Ess Fatty Acids 1991;44:177-184.
54. 2 of the upper aerodigestive tract. Ann Otol Rhinol Laryngol 1987;96:213-216.
55. Braun D, Harris J. The impact of prostaglandins on cancer patient immunity. In: Harris JE, Braun DP, Anderson KM, eds. Prostaglandin inhibitors in tumor immunology and immunotherapy. Boca Raton: CRC Press, 1994.
56. Young M. Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 1994;13:337-348.
57. Remacle J, Raes M, Toussaint, et al. Low levels of reactive oxygen species as modulators of cell function. Mutat Res 1995;316:103-122.
58. Marnett L. Generation of mutagens during arachidonic acid metabolism. Cancer Metastases Rev 1994;13: 303-308.
59. Powis G, Gasdaska JR, Baker W. Redox signalling and the control of cell growth and death. Adv Pharmacol 1997; 38:329-41.
60. Klapan I, Katic V, Culo F, Cuk V. Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer. J Cancer Res Clin Oncol 1992;118: 308-313.
61. Cenik Z, Uyar Y. Larynx cancer and prostaglandins. Am J Otolaryngol 1990;11:81-84.
62. 2 and prostacyclin concentrations in squamous cell carcinoma of the head and neck. J Surg Oncol 1988;38:33-37.
63. 2 half-life in patients with maxillo-facial tumors. Prog Clin Biol Res 1987;242:123-129.
64. Malone J, Snyderman CH. Arachidonic acid metabolites in saliva of patients with squamous cell carcinoma of the head and neck. Oral Surg Oral Med Oral Pathol 1994;77: 636-640.
65. Metzger K, Angres G, Maier H, et al. Lipoxygenase products in human saliva: patients with oral cancer compared to controls. Free Radical Biol Med 1995;18:185-194.
66. Fischer S, Mills G, Slaga T. Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism. Carcinogenesis 1982;3:1243-1245.
67. Scioscia K, Snyderman C, Rueger R, et al. Role of arachidonic acid metabolites in tumor growth by non-steroidal anti-inflammatory drugs. Am J Otolaryngol 1997;18:1-8.
68. Snyderman C, Abbas M, Wagner R, D'amico F. Inhibition of growth of a murine squamous cell carcinoma by a cyclooxygenase inhibitor increases leukotriene B4 production. Arch Otolaryngol Head Neck Surg 1995;121: 1017-1020.
69. Karmali RA, Wustrow T, Thaler HT, Strong EW. Prostaglandins in carcinomas of the head and neck. Cancer Lett 1984;22:333-336.
70. Jung T, Berlinger N, Juhn S. Prostaglandins in squamous cell carcinomas of the head and neck: a preliminary study. Laryngoscope 1985;307:95-101.
71. Berlinger N. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 1984;94:107-112.
72. Heidenreich S, Gong J, Schmidt, et al. Macrophage activation by GM-CSF: priming for enhanced release of TNF-alpha and PG E2. J Immunol 1989;143:1198-1205.
73. Portender H, Matejka M, Ulrich W, Sinzinger H. The cyclooxygenase and lipoxygenase pathways in human oral cancer tissue. J Maxillofac Surg 1984;12:145-147.
74. Pinto S, Gallo O, Dilaghi M, et al. Prostaglandins in squamous cell carcinoma of the larynx: tumor and peritumor synthesis. Prostagland Leukotri Essent Fatty Acids 1990; 39:53-57.
75. Mann E, Spiro J, Chen L, Kreutzer D. Phospholipid metabolite expression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1994;120: 763-769.
76. Snyderman C, Klapan I, Milanovich M, et al. Comparison of in vivo and in vitro PG E2 production by squamous cell carcinomas of the head and neck. Otolaryngol Head Neck Surg 1994;11:189-196.
77. Milanovich M, Snyderman C, Wagner R, et al. Prognostic significance of PG E2 production by mononuclear cells and tumor cells in squamous cell carcinomas of the head and neck. Laryngoscope 1995;105:61-65.
78. Snyderman C, Milanovich M, Wagner R, et al. Prognostic significance of PG E2 production in fresh tissues of head and neck cancer patients. Head Neck 1995;17:108-113.
79. Young M, Wright M, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer. Intl J Cancer 1996;67:333-338.
80. Cross DS, Platt JL, Juhn SK, Bach FH, Adams GL. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992;118:526-528.
81. El Attar TM, Lin HS. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs. J Oral Pathol 1987;16:483-487.
82. Suzuki K, Kobayashi N, Moriya Y, Abiko Y, Suzuki H. Inhibition of human gingival carcinoma cell growth by prostaglandins. Gen Pharmacol 1988;19:273-276.
83. Carter RL. Patterns and mechanisms of localized bone invasion by tumors: studies with squamous carcinomas of the head and neck. CRC Crit Rev Clin Lab Sci 1982;22: 275-315.
84. Tsao SW, Burman JF, Pittam MR, Carter RL. Further observations on mechanisms of bone destruction by squamous carcinomas of the head and neck: the role of host stroma. Br J Cancer 1983;48:697-704.
85. El Attar TM, Lin HS. Effect of retinoids and carotenoids on prostaglandin formation by oral squamous carcinoma cells. Prostagland Leukotr Essent Fatty Acids 1991;43: 175-178.
86. El Attar TM, Lin HS. Effect of Vitamin C and Vitamin E on prostaglandin synthesis by fibroblasts and squamous carcinoma cells. Prostagland Leukotr Essent Fatty Acids 1992;47:1253-1257.
87. Anderson KM, Ondrey F, Harris JE. Arachidonic acid analogues: an additional class of membrane-active agents with potential anticancer activity. Prostagland Leukotri Essent Fatty Acids 1989;35:231-241.
88. 4 and oral cancer. Br J Oral Maxillofac Surg 1990;28:155-159.
89. 4 in head and neck cancer (letter). Br J Cancer 1989;59:833.
90. Ondrey F, Juhn S, Adams G. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106:129-134.
91. Ondrey FG, Juhn SK, Anderson KM, Adams GL. Decreased DNA synthesis in SCC-25 cells with ETYA and SC41661. Third international conference on eicosanoids and other bioactive lipids in cancer, inflammation, and radiation injury, volume 3, 1997.
92. Panje WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol Head Neck Surg 1981;107:658-660.
93. Suen J, Simonton-Atchley S. Spontaneous remission of head and neck cancer: a report of 5 cases. #74, 4TH International Conference on Head and Neck Cancer, 1996.